Compounds > N-[4-(3-chloro-4-fluoroanilino)-3-cyano-7-ethoxy-6-quinolinyl]-4-(dimethylamino)-2-butenamide
Page last updated: 2024-09-05

N-[4-(3-chloro-4-fluoroanilino)-3-cyano-7-ethoxy-6-quinolinyl]-4-(dimethylamino)-2-butenamide and lenvatinib

N-[4-(3-chloro-4-fluoroanilino)-3-cyano-7-ethoxy-6-quinolinyl]-4-(dimethylamino)-2-butenamide has been researched along with lenvatinib in 1 studies

Compound Research Comparison

Studies
(N-[4-(3-chloro-4-fluoroanilino)-3-cyano-7-ethoxy-6-quinolinyl]-4-(dimethylamino)-2-butenamide)		Trials
(N-[4-(3-chloro-4-fluoroanilino)-3-cyano-7-ethoxy-6-quinolinyl]-4-(dimethylamino)-2-butenamide)		Recent Studies (post-2010)
(N-[4-(3-chloro-4-fluoroanilino)-3-cyano-7-ethoxy-6-quinolinyl]-4-(dimethylamino)-2-butenamide)		Studies
(lenvatinib)		Trials
(lenvatinib)		Recent Studies (post-2010) (lenvatinib)
907975112946

Protein Interaction Comparison

ProteinTaxonomyN-[4-(3-chloro-4-fluoroanilino)-3-cyano-7-ethoxy-6-quinolinyl]-4-(dimethylamino)-2-butenamide (IC50)lenvatinib (IC50)
Proto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)0.0162
Platelet-derived growth factor receptor betaHomo sapiens (human)0.039
Platelet-derived growth factor receptor alphaHomo sapiens (human)0.051
Vascular endothelial growth factor receptor 1 Homo sapiens (human)0.022
Kinesin-1 heavy chainHomo sapiens (human)0.01
Vascular endothelial growth factor receptor 3Homo sapiens (human)0.0052
Vascular endothelial growth factor receptor 2Homo sapiens (human)0.0035
Nuclear receptor coactivator 4Homo sapiens (human)0.01
Coiled-coil domain-containing protein 6Homo sapiens (human)0.01

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ1

Other Studies

1 other study(ies) available for N-[4-(3-chloro-4-fluoroanilino)-3-cyano-7-ethoxy-6-quinolinyl]-4-(dimethylamino)-2-butenamide and lenvatinib

ArticleYear
Identification of potent Yes1 kinase inhibitors using a library screening approach.
    Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15

    Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship

2013